| 证券代码 | CNST.O |
| 证券名称 | Constellation Pharmaceuticals Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2018-07-19 |
| 首发价格(元) | 15 USD |
| 首发数量(股) | 4000000 |
| 首发募资额(元) | 60,000,000.00 USD |
| 首发主承销商 | J.P. Morgan Securities LLC,Jefferies LLC |
| 货币单位 | USD |
| 公司名称 | Constellation Pharmaceuticals, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 215 First Street, Suite 200, Cambridge, Massachusetts, USA |
| 成立日期 | 2008-01-11 |
| 董事会主席 | Mark A. Goldsmith |
| 公司属地 | United States 美国 |
| 公司网址 | www.constellationpharma.com |
| 电话 | +1 (617) 714-0555 |
| 传真 | +1 (617) 577-0472 |
| 公司简介 | Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its integrated epigenetics platform enables us to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Platform insights and clinical experience guide development of its wholly owned lead product candidates: CPI-1205 which inhibits enhancer of zeste homolog 2, or EZH2, and CPI-0610 which inhibits bromodomain and extra terminal domain, or BET, proteins. |